Molinatti G M, Messina M, Monaco A, Passera P
Cattedra di Medicina Interna, Università degli Studi di Torino.
Minerva Endocrinol. 1993 Mar;18(1):1-11.
Androgenization in women can be divided, from a clinical standpoint, in two groups: a major form (with hirsutism, seborrhea, acne, hair loss, menstrual irregularities, masculinization of muscles and voice, mammary atrophy) and a minor one, with skin changes only (in particular hirsutism) with or without menstrual problems. The different clinical presentations are reviewed here: virilizing tumours of adrenal glands and ovaries, adrenogenital congenital syndromes, Cushing's syndrome and disease, iatrogenic forms, simple or idiopathic hirsutism, late onset enzymatic defects of adrenal steroidogenesis, polycystic ovary syndrome). The relevant therapeutic options are discussed. Special attention is devoted to the treatment of simple cutaneous androgenization, a problem affecting about 10% of women, by antiandrogenic drugs, mostly cyproterone acetate and spironolactone. These compounds compete with dehydrotestosterone for androgen cutaneous receptors, and have obtained good results, although not permanent. The indications, use and side-effects are also discussed.
从临床角度来看,女性雄激素化可分为两组:主要形式(伴有多毛症、脂溢性皮炎、痤疮、脱发、月经不调、肌肉和嗓音男性化、乳腺萎缩)和次要形式,仅伴有皮肤变化(特别是多毛症),有或无月经问题。本文回顾了不同的临床表现:肾上腺和卵巢的雄激素化肿瘤、先天性肾上腺皮质增生症、库欣综合征及疾病、医源性形式、单纯性或特发性多毛症、肾上腺类固醇生成酶延迟缺陷、多囊卵巢综合征)。文中讨论了相关的治疗选择。特别关注了通过抗雄激素药物(主要是醋酸环丙孕酮和螺内酯)治疗单纯性皮肤雄激素化的问题,这一问题影响约10%的女性。这些化合物与脱氢睾酮竞争皮肤雄激素受体,并取得了良好效果,尽管并非永久性的。文中还讨论了其适应症、用法和副作用。